Famar to acquire Roche's Leganes site
Site provides Famar with capacities and expertise in the production of solid dosage forms with high-potency APIs, which represents new technology for the company.
Famar and Roche have signed an agreement for the acquisition by Famar of the Leganes site. The two partners have signed in parallel a long-term manufacturing agreement that will allow Famar Leganes to supply Roche in the future from this facility with the current portfolio of products produced at the site.The transfer of full ownership of the Leganes site is expected to be completed 1 July 1 2016.
Famar is a leading contract manufacturing rganization to the pharmaceutical and health and beauty markets, and ranked amongst the top 5 in this sector. Presently, it has an existing network of 11 manufacturing sites in Europe, which supply a wide range to the industry, serving most international markets, with a broad customer base.
The Leganes site is modern, well equipped and is approved for worldwide supply. It provides Famar with capacities and expertise in the production of solid dosage forms with high-potency active pharmaceutical ingredients, which represents new technology for the company and adds to Famar's technology portfolio in solid dosage formulations.
Because the Leganes site is FDA certified, it will give Famar access to the US market, which Famar anticipates will help to accelerate growth. By early 2017, Famar is expected to have two FDA approved sites in their global network, the other one is based in Canada.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.